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Abstract 25
Ornithodoros moubata is the main vector of the pathogens causing African swine fever 26
and human relapsing fever in Africa. The development of an efficient vaccine against 27
this tick would facilitate its control and the prevention of the diseases it transmits to a 28
considerable extent. Previous efforts to identify vaccine target candidates led us to the 29
discovery of novel salivary proteins that probably act as anti-haemostatics at the host-30
tick interface, including a secreted phospholipase A2 (PLA2), a 7DB-like protein (7DB-31
like), a riboprotein 60S L10 (RP-60S), an apyrase (APY), and a new platelet aggregation 32
inhibitor peptide, designated mougrin (MOU). In this work, the corresponding 33
recombinant proteins were expressed in Escherichia coli and their individual vaccine 34
efficacy was tested in rabbit vaccination trials. All of them, except the less 35
immunogenic RP-60S, induced strong humoral responses that reduced tick feeding and 36
survival, providing vaccine efficacies of 44.2%, 43.2% and 27.2%, 19.9% and 17.3% for 37
PLA2, APY, MOU, RP-60S and 7DB-like, respectively. In the case of the more protective 38
recombinant antigens (PLA2, APY and MOU), the immunodominant protective linear B-39
cell epitopes were identified and their combined vaccine efficacy was tested in a 40
second vaccine trial using different adjuvants. In comparison with the best efficacy of 41
individual antigens, the multicomponent vaccine increased vaccine efficacy by 13.6%, 42
indicating additive protective effects rather than a synergistic effect. Tick saliva 43
inoculated during natural tick-host contacts had a boosting effect on vaccinated 44
animals, increasing specific antibody levels and protection. 45
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Highlights 51
52
 Five new recombinant salivary anti-haemostatics from O. moubata were tested as 53
vaccine antigens. 54
 Recombinant PLA2, APY and MOU induced valuable protective responses. 55
 Joint administration of these three protective antigens increased vaccine efficacy. 56
 Tick infestations boost protection by acting as natural re-vaccination events. 57
58
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1. Introduction. 59
The argasid tick Ornithodoros moubata is distributed throughout South and East 60
Africa and Madagascar, where it colonizes wild and domestic habitats and feeds on 61
warthogs, domestic swine and humans (Vial, 2009). O. moubata transmits both the 62
African swine fever (ASF) virus and the tick-borne human relapsing fever (TBRF) agent 63
Borrelia duttoni. The presence of this tick in domestic and peridomestic environments 64
contributes to the persistence of ASF and TBRF in endemic areas and may facilitate the 65
spread of these diseases into surrounding areas (Cutler, 2010; Costard et al., 2013; 66
EFSA panel, 2014; Sánchez-Vizcaíno et al., 2015). Therefore, the elimination of O. 67
moubata from synanthropic environments would greatly improve the prevention and 68
control of such diseases. 69
Anti-tick vaccines have proved to be a feasible, cost-effective and environmental-70
friendly method for the control of tick infestations, avoiding many of the drawbacks 71
associated with the use of chemical acaricides (de la Fuente et al., 2007; Willadsen, 72
2008a; Guerrero et al., 2012).  73
Investigations for the development of vaccines against O. moubata began with 74
Chinzei and Minoura (1988) and Astigarraga et al. (1995), who tested the protective 75
effect of concealed antigens from tick eggs and exposed antigens from tick salivary 76
glands, respectively. Subsequent investigations using salivary and concealed antigens 77
have identified some promising vaccine candidates, but currently an effective vaccine 78
against O. moubata is still lacking (Díaz-Martín et al., 2015). 79
Regarding studies involving salivary antigens, Astigarraga et al. (1995) observed 80
that pig vaccination with salivary gland extracts (SGE) induced protective responses, 81
and that the sera from protected pigs recognized an antigen of 44 kDa (hence the 82
name Om44), which was never recognized by the sera from non-protected pigs 83
sensitized by natural infestation. In addition, vaccination with the purified Om44 84
antigen was shown to provide similar protection to SGE and this protection was 85
observed to increase with successive O. moubata infestations (García-Varas et al., 86
2010). The functional characterization of Om44 revealed that it acts as an antagonist 87
ligand for host P-selectin, preventing the P-selectin-mediated haemostatic and 88
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inflammatory host response at the tick bite site and hence enabling ticks to complete 89
their blood feeding (Cleator et al., 2006; García-Varas et al., 2010). 90
The identification of Om44 was first attempted by mass spectrometry; this was 91
unsuccessful, although the mass spectrometric data did reveal that Om44 was not an 92
orthologue of well-established P-selectin ligands, including PSGL-1 and pentraxin 3 93
(García-Varas et al., 2010). Next, taking into account that protein microarrays are 94
powerful tools that allow the identification of molecular partners interacting at the 95
host-pathogen interface (Manzano-Román et al., 2013), self-assembled nucleic acid 96
programmable protein microarrays (NAPPA) were constructed from O. moubata97
salivary gland cDNA expression libraries. In order to identify Om44, these arrays were 98
screened using a P-selectin/IgG chimera and an anti-Om44 polyclonal serum as probes. 99
The results of this screening indicated that Om44 is a salivary secreted phospholipase 100
A2 (PLA2) that binds P-selectin through protein-protein interactions without the 101
involvement of glycan moieties (Manzano-Román et al., 2012). Consequently, it was 102
speculated that this PLA2 might be an important candidate for vaccine development. 103
Additionally, the anti-Om44 serum recognized another four salivary proteins in the 104
microarray screening: a putative 7DB family member (7DB-like), riboprotein 60S L10 105
(RP-60S), heat shock protein 90 (HSP90) and actin (Manzano-Román et al., 2012). With 106
the exception of actin, these proteins might have also contributed to the protective 107
responses induced by the SGE and the purified Om44 antigen, so they could also be 108
regarded as candidate antigens for vaccine development. Actin was excluded as a 109
potential vaccine antigen owing to its high degree of conservation between ticks and 110
mammals and to the lack of protective effects observed by us in a preliminary vaccine 111
trial (unpublished) and by other authors using actin in vaccine trials against other 112
parasites (Zheng et al., 2013). 113
Moreover, a preliminary partial random sequencing of the above-mentioned 114
libraries allowed us to identify two novel salivary proteins of O. moubata: an apyrase 115
(APY) and a platelet-aggregation inhibitor peptide orthologous to the savignyigrin of O. 116
savignyi, which was called mougrin (MOU) (Manzano-Román et al., 2012; Díaz-Martín, 117
2014). Owing to the potential anti-haemostatic activity of these proteins (Chmelar et 118
al., 2012), they were also considered to be interesting candidate antigens for anti-tick 119
vaccines. 120
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Thus, the main objective of the present work was to assess the protective 121
efficacy of these salivary proteins, including the identification of potentially protective 122
linear B-cell epitopes. With this aim, these proteins were produced in recombinant 123
form and tested in vaccine trials, both individually and administered jointly to evaluate 124
potentially additive protective effects, and were formulated in different adjuvants to 125
evaluate the most adequate antigen-adjuvant combination. 126
127
2. Materials and Methods. 128
129
2.1. Ticks and tick material. 130
The O. moubata ticks used in this study came from a colony currently maintained 131
at the laboratory of Animal Parasitology (IRNASA, CSIC, Spain). This colony was 132
established from specimens submitted from the Institute for Animal Health, Pirbright, 133
Surrey, UK. The ticks are fed regularly on rabbits and kept in a culture chamber at 28 134
ºC, with 85 % relative humidity and a 12 h light-dark cycle. 135
Tick saliva was collected from unfed adult ticks after stimulating them with 1% 136
pilocarpine, as described previously (Díaz-Martín et al., 2013). Protein concentrations 137
in saliva samples were measured with the Bradford assay (Bio-Rad) and samples were 138
stored at -20 ºC. 139
Total RNA from the salivary glands of unfed adult ticks (10 males + 10 females) 140
was purified using the NucleoSpin RNA II kit (Macherey-Nagel), following the 141
manufacturer’s,instructions, and preserved at -80 ºC. 142
143
2.2. Cloning, expression and purification of recombinant proteins. 144
145
2.2.1. Starting material. 146
Recombinant plasmids containing the cDNA coding sequences of the proteins of 147
interest were obtained from salivary gland cDNA libraries constructed previously 148
(Manzano-Román et al., 2012).  149
Plasmids containing the complete cDNA coding sequences of APY and MOU came 150
from the entry library cloned in pDNOR_222 (Invitrogen), while plasmids containing 151
the complete cDNA coding sequences of PLA2, 7DB-like and RP-60S came from the 152
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expression library cloned in pANT_GST (DNASU Plasmid Repository). These plasmids 153
were used as templates for amplification of the target sequences (Table 1). 154
For HSP90, the recombinant plasmid available (pANT_GST-HSP90) contained an 155
incomplete cDNA fragment lacking, the, 5’, en. Thus, the missing sequence was first 156
obtaine,by,5’-RACE from total RNA of salivary glands using the First Choice RLM-RACE 157
kit (Life Technologies) accoring, to, the,manufacturer’s, instructions, and two primers 158
that were designed ad hoc: GSP2-HSP90 (5’-AATAGATGTGCTTCTGGTTTTCCTTC) and 159
GSP3-HSP90 (5’-ATATTTTTGCTGAACTGCTCATAGAA). Once its 5’, en was known, the 160
complete cDNA coding sequence of HSP90 was amplified from total RNA with primer 161
pair Hsp90Kpn55/Hsp90Kpn33 (Table 1). The PCR product was purified and cloned into 162
the pSC-A sequencing vector (Agilent) and its sequence was confirmed following 163
standard procedures described elsewhere (Díaz-Martín et al., 2011). The verified pSC-164
A-HSP90 construction was used as a template for PCR amplification and the sub-165
cloning of HSP90 (Table 1). 166
The complete nucleotide sequences coding for these proteins were uploaded 167
into GenBank and the corresponding amino acid sequences were subjected to a basic 168
computational analysis for the identification of restriction enzyme sites, signal 169
peptides, non-classic secretion signals, transmembrane helices and GPI anchor sites, 170
using the appropriate tools available at the Expasy website (http://www.expasy.org/) 171
as reported elsewhere (Díaz-Martín et al., 2013). 172
173
2.2.2. PCR amplification of target sequences and subcloning into expression 174
vectors. 175
For amplification of the coding cDNAs, six specific primer pairs were designed 176
that included suitable restriction sites to assist in the sub-cloning into the 177
corresponding expression vector. These primer pairs amplified the whole coding 178
sequences except the pairs designed for 7DB-like and APY, which amplified truncated 179
versions, with no signal peptide, of the corresponding protein. All the proteins except 180
MOU were cloned into the pQE-30 expression vector (Qiagen). Owing to its small size 181
(63 amino acids), MOU was cloned into pGEX-4T-1 (Amersham) in order to produce it 182
as a larger fusion protein (MOU-GST) and to improve its immunogenicity. Table 1 183
summarizes all the templates and primers used in the PCR amplifications as well as the 184
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restriction enzymes and expression vectors involved. Table 2 compiles the specific 185
conditions for the different PCRs. The PCR products were purified, digested and cloned 186
into the corresponding expression vector following standard procedures described in 187
previous works (de la Torre et al., 2010; Díaz-Martín et al., 2011). 188
189
2.2.3. Protein expression and purification. 190
Recombinant pQE-30 plasmids containing PLA2, 7DB-like, RP-60S, HSP90 and APY 191
were transformed into E. coli M15 cells and protein expression was induced with 1 mM 192
IPTG. Except for HSP90, whose expression failed, all these proteins were expressed in 193
100 % insoluble form. Thus, they were solubilized with 8 M urea, purified by nickel 194
affinity chromatography in denaturing conditions, and dialyzed against phosphate-195
buffered saline (PBS), pH 7.4, for 24 h at 4 ºC according to the procedure described by 196
Díaz-Martín et al. (2011). 197
The recombinant pGEX-4T-1-MOU plasmid was transformed into E. coli BL21 cells 198
and protein expression was induced with 0.1 mM IPTG. The MOU-GST fusion protein 199
was expressed in 100 % insoluble form, and was therefore purified from the cellular 200
lysate pellet by electroelution from SDS-PAGE gels following the procedure described 201
by Harlow and Lane (1988). 202
The concentrations of the purified proteins were measured by 203
spectrophotometry at 280 nm and proteins were stored at -20 ºC.  204
205
2.3. Vaccine trials. 206
2.3.1. Trial 1. 207
The aim of this trial was to assess the individual capacity of the above 208
recombinant antigens to induce protective responses in rabbits. Each recombinant 209
protein was,aministere,to,a,group,of,three,rabbits,(New,Zealan,white),in,Freun’s,210
adjuvant. Two additional groups of rabbits were immunized, either with recombinant 211
GST from Schistosoma japonicum (rSjGST; Sigma) in, Freun’s, ajuvant, or, with, the 212
adjuvant alone, and used as controls. 213
Each animal was vaccinated at 15-day intervals with three doses of 200 µg of 214
protein per dose administered subcutaneously. The first dose was administered 215
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emulsifie, in, Freun’s, complete, ajuvant, (FC;), the, secon, in Freun’s, incomplete,216
adjuvant (FIA), and the third dose with no adjuvant. 217
Rabbits were bled immediately before the administration of the first dose (pre-218
immune sera) and at seven days after the third one, immediately before tick 219
infestation (immune sera). Blood samples were allowed to clot and sera were removed 220
and stored at -80 ºC. In the immune sera, the antibody titres to the homologous 221
recombinant protein were tested by ELISA and their reactivity to O. moubata saliva 222
was tested by ELISA and Western blot according to standard procedures (García-Varas 223
et al., 2010; Manzano-Román et al., 2015). 224
At seven days after the third antigen dose, all rabbits were infested with 15 225
females, 25 males and 50 nymphs-2 of O. moubata per rabbit. The parasites were 226
allowed to feed on the rabbits for a maximum of 2 hours after which they were 227
removed from the animals. The degree of protection was determined by measuring 228
the amount of blood ingested (difference in tick weight before feeding and 24 hours 229
after feeding), the oviposition (number of eggs per female) and fertility (number of 230
nymphs-1 per female) rates, the moulting rates of immature stages and the mortality 231
rates of all developmental stages. 232
The values obtained for the parasites fed on the animals from each group were 233
summarized as means ± standard deviations. Statistical differences between the 234
vaccinated and control group were assessed by one-way ANOVA followe,by,Dunnett’s,235
t-test. Values of p < 0.05 were considered significant. 236
Vaccine efficacy (E) was calculated as E = 100 (1- S x F), where S and F 237
respectively represent the reduction in female survival and fertility in ticks fed on 238
vaccinated rabbits as compared to those fed on control rabbits (treated with adjuvant 239
alone or with adjuvant + rSjGST). 240
241
2.3.2. Trial 2. 242
The goal of this trial was to assess the joint vaccine efficacy of PLA2, APY and 243
MOU formulated together in different adjuvants (Freun’s or Montanide ISA 50 V2, 244
Seppic) with or without an immune-stimulant (namely, the TLR9 agonist CpG ODN-245
1826, Miltenyi Biotec). 246
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With this aim, antigen doses containing 100 µg of each recombinant protein in 1 247
ml of PBS were prepared and administered to different groups of 3 rabbits per group 248
as follows. Group 1: the antigen mixture was supplemented with 100 µg/dose of ODN-249
1826 and emulsified in 1 ml of Montanide ISA 50 V2. Group 2: the antigen mixture was 250
emulsified in Montanide without ODN-1826. Group 3: the antigen mixture was 251
emulsified in FCA and FIA, respectively, for the first two doses and without adjuvant 252
for the third dose. Each rabbit received three antigen doses subcutaneously at 3-week 253
intervals. An additional group of three rabbits was treated with Montanide ISA 50 V2 254
plus ODN-1826 and used as control. 255
Rabbits were bled immediately before the administration of the first dose (pre-256
immune sera) and at 14 and 28 days after the third one (immune sera), immediately 257
before tick infestations. Blood samples were allowed to clot and sera were removed 258
and stored at -80 ºC. In the immune sera, the antibody titres to each recombinant 259
protein and the reactivity to O. moubata saliva were tested by ELISA as described 260
previously (Manzano-Román et al., 2015). 261
At 14 and 28 days after the third antigen dose, all rabbits were subjected to two 262
tick infestations with 15 females, 25 males and 50 nymphs-3 of O. moubata per rabbit 263
and infestation. The tick infestations, the assessment of vaccine effects on the 264
parasites, and the calculation of vaccine efficacies were accomplished as described 265
before for trial 1. Additionally, the vaccine efficacies of each treatment were compared 266
between infestations using Stuent’s,T,test267
All animal manipulations were performed according to the rules from the Ethical 268
and Animal Welfare Committee of the Institution where the experiments were 269
conducted (IRNASA, CSIC), following the corresponding EU rules and regulations. 270
271
2.4. Peptide arrays and epitope mapping (pepscan). 272
Pepscans were performed on PLA2, APY and MOU to identify the linear B-cell 273
epitopes recognized by the protected animals from trial 1. 274
With this aim, peptide arrays of PLA2, APY and MOU were synthesized and 275
spotted onto cellulose sheets at the Proteomics Service of the Centro Nacional de 276
Biotecnología (Madrid, Spain). Each sheet contained 2 identical replicas of 88, 192 and 277
18 overlapping 12-mer peptides with 9 amino acid overlaps, which covered the entire 278
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sequence of the PLA2 (AGJ90343.1), APY (AGJ90350.1) and MOU (AGJ90345.1), 279
respectively (Suppl. Fig. 1).  280
Pepscans were carried out as already described (Manzano-Román et al., 2015). 281
Before use, the sheets were submerged in ethanol to facilitate the hydration of 282
hydrophobic peptides, rinsed 3 times (10 min each) in 50 mM Tris, 150 mM NaCl (TBS), 283
pH 7, and then blocked in TBS containing 5% skimmed milk, 5% sucrose and 0.05% 284
Tween 20 (blocking solution) overnight at 4 ºC. Then, they were washed in TBS 285
containing 0.05% Tween 20 (washing buffer) and incubated with the corresponding 286
serum pool diluted 1/1,000 in blocking solution for two hours at room temperature 287
(RT). Three serum pools specifically recognizing PLA2, APY and MOU were prepared 288
from the immune sera obtained in vaccine trial 1. After 3 washes, the sheets were 289
incubated with peroxidase-conjugated anti-rabbit IgG diluted 1/10,000 in blocking 290
solution for two hours at RT. After six new washes, the sheets were incubated with 291
Immun-Star WesternC (BIO-RAD) for 5 min at RT. 292
Negative controls included sheets processed without the primary antibodies or 293
with the pooled pre-immune sera from trial 1, or with the pooled immune sera from 294
animals immunized with rSjGST. 295
The membranes were scanned with a ChemiDoc device using Image Lab software 296
(BIO-RAD). Image analysis was carried out using Image Master 2D platinum software 297
(GE Healthcare Life sciences), including quantification of the volume of the spots 298
recognized. A peptide was considered positively bound to the antibody when the 299
signal of the corresponding spot was higher than two-fold the average signal of the 300
spots revealed in the negative control membranes. Linear B-cell epitopes were 301
considered only when two or more positive consecutive peptides were recognized in 302
the protein sequence. 303
304
2.5. Computational analysis, 3-D modelling and linear B-cell epitope prediction. 305
The secondary structure and disordered regions of PLA2, APY and MOU were 306
predicted using the Phyre2 (Kelley and Sternberg, 2009), the Disopred2 Disorder 307
prediction (Ward et al., 2004) and the I-Tasser (Zhang, 2008; Roy et al., 2010) servers. 308
For each protein, the three predictions were aligned and the consensus secondary 309
structures were obtained. Three-dimensional (3-D) models of the proteins were 310
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generated using the I-Tasser server and the 3-D models were visualised and handled 311
using the PyMol package (DeLano, 2002). 312
For linear B-cell epitope prediction, the BcePred:prediction and the ABCpred 313
Prediction servers were employed using default parameters (Saha and Raghava, 2004, 314
2006). 315
316
3. Results. 317
318
3.1. Nucleotide and amino acid sequences. 319
 Complete cDNA coding sequences of the target proteins were verified and 320
uploaded into GenBank with the accession numbers indicated in table 3. In silico321
translations and analysis of the corresponding amino acid sequences revealed that 322
7DB-like, APY and MOU had signal peptide while PLA2, 7DB-like and APY had non-323
classical secretion and RP-60S and HSP90 lacked any secretion signal, classical or not. 324
Only MOU had a predicted transmembrane helix and none of them had GPI anchors 325
(Table 3). 326
327
3.2. Recombinant protein production. 328
The full-length recombinant forms of PLA2 and RP-60S, the truncated versions of 329
7DB-like and APY, and the MOU-GST fusion protein were all successfully expressed and 330
purified (Fig. 1). All of them migrated in SDS-PAGE gels as a single band of the 331
predicted molecular weight (MW), except 7DB-like, which showed an experimental 332
MW of twice its theoretical MW (24 kDa vs. 12.28 kDa). The identity of this 333
recombinant as the predicted 7DB-like was later confirmed by MALDI-TOF/TOF mass 334
spectrometry analysis of the corresponding gel band; this suggests a possible 335
dimerization of this recombinant. 336
Regarding HSP90, after inducing its expression with IPTG the optical density of 337
the cell culture decreased and no recombinant protein was recovered from the cell 338
lysate. Additional attempts to express HSP90 in different cell culture and induction 339
conditions also failed, suggesting cell toxicity. Consequently, this protein was excluded 340
from ensuing experiments. 341
342
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3.3. Vaccination trial 1. Humoral immune response and protective effects induced by 343
the individual recombinant antigens.344
 The immune sera from vaccinated rabbits showed high reactivity to the 345
homologous recombinant antigen, reaching optical densities (ODs) between 0.8 and 346
1.6 and IgG antibody titres higher than 1/12,800. The only exceptions were the sera 347
from rabbits vaccinated with RP-60S, which had ODs around 0.4 and average IgG titres 348
of 1/1,600 (Fig. 2A). When tested against the O. moubata saliva, the sera to PLA2, APY 349
and MOU showed medium-low reactivity (OD between 0.2 and 0.4), while the sera to 350
7DB-like and RP-60S showed low reactivity (OD between 0.2 and 0.1), i.e., barely 351
surpassing that of the pre-immune sera (Fig. 2A). 352
According to Western blot, each immune serum recognized a single band of the 353
expected size on its homologous recombinant antigen, excluding the anti-PLA2 sera, 354
which revealed 3 bands of nearly 34, 68 and 100 kDa, suggesting oligomerization of the 355
recombinant PLA2 (Fig. 2B). Furthermore, the sera to PLA2, APY and MOU-GST also 356
recognized their corresponding native antigens on the O. moubata saliva (Fig. 2C): anti-357
APY sera revealed a single band of the expected size, anti-PLA2 sera revealed a single 358
band of 68 kDa (twice the size of the monomeric recombinant) and anti-MOU-GST sera 359
revealed a single band matched in size with GST protein but not MOU (7.2 kDa). By 360
contrast, the sera to 7DB-like and RP-60S did not recognize any band on saliva (Fig. 2C). 361
The protective effect of vaccination was assessed by infesting each rabbit with 362
25 males, 15 females and 50 nymphs-2 of O. moubata. No differences were observed 363
between the two control groups (adjuvant, SjGST) for any developmental stage in any 364
of the parameters evaluated. Accordingly, these two groups were merged and treated 365
as a single control group. 366
Protection mainly consisted of decreases in the feeding, reproduction and 367
survival of the ticks fed on vaccinated animals as compared to the ticks fed on controls 368
(Table 4), while unimportant differences were observed in the moulting rate of 369
nymphs between the vaccinated ticks and the controls (not shown). 370
Significant reductions were recorded in the amount of blood ingested by 371
females and nymphs fed on all vaccinated rabbits and by males fed on rabbits 372
vaccinated with APY and MOU. APY induced the strongest reductions in feeding in all 373
developmental stages. Highly significant reductions in female oviposition and fertility 374
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were observed for the rabbits vaccinated with PLA2, APY and MOU, while less 375
significant or non-significant reductions in these parameters were recorded in the 376
rabbits vaccinated with RP-60S and 7DB-like. Regarding mortality, significant increases 377
were recorded for all developmental stages fed on rabbits vaccinated with PLA2, as 378
well as for males fed on rabbits vaccinated with APY and for females and nymphs fed 379
on rabbits vaccinated with RP-60S (Table 4). 380
 Vaccine efficacy (E) was calculated for each recombinant antigen based on the 381
decreases in female survival and fertility, since these parameters are largely 382
responsible for the size of the next tick generation and hence the evolution of the tick 383
population. Here, the most protective antigen was PLA2 (44.2 %), followed by MOU 384
(43.2 %) and APY (27.2 %). The least protective ones were 7DB-like (12 %) and RP-60S 385
(19.9 %), which showed efficacies lower than 20 %, although these efficacies were also 386
statistically significant with respect to the control group (Fig. 3). 387
388
3.4. Linear B-cell epitopes recognized on the PLA2, APY and MOU by the vaccine-389
induced anti-recombinant antibodies. 390
To map their linear B-cell epitopes, PLA2, APY and MOU peptide arrays were 391
scanned with the sera from rabbits immunized with recombinant PLA2, APY and MOU. 392
Control sheets processed without primary antibodies did not reveal any spots 393
on any of the arrays (not shown), while the negative pre-immune sera and the sera to 394
SjGST revealed some scattered faint spots on the three peptide arrays, whose volume 395
values served to calculate the threshold for positivity (Suppl. Fig. 1; Suppl. Table 1).  396
The sera to PLA2, APY and MOU only revealed B-cell linear epitopes on their 397
homologous protein, indicating a lack of cross-reactivity between them (Suppl. Fig. 1; 398
Suppl. Table 1). On PLA2, the antibodies revealed three strongly reactive epitopes and 399
eight epitopes with medium-low reactivity; on APY the antibodies revealed two strong 400
and seven medium-low reactive epitopes, and on MOU the antibodies revealed just 401
two strong overlapping epitopes. For PLA2 and APY, most of their linear B-cell epitopes 402
mapped onto structured regions of proteins (mainly α-helices), while for MOU the two 403
B-cell epitopes mapped onto the disordered central region of the protein (Fig. 4A). 404
Three dimensional models of PLA2, APY and MOU showed that all the epitopes 405
strongly recognized by the antibodies were located on the surface of the molecules 406
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(Fig. 4B), while the epitopes recognized less intensely were located deeper inside the 407
molecules, where they are probably less accessible to antibodies (not shown).   408
409
3.5. Prediction of theoretical linear B-cell epitopes. 410
For PLA2, the ABCpred and BcePred servers predicted two different sets of 7 411
and 8 epitopes respectively (Suppl. Fig. 2). The epitopes of each set were distributed 412
throughout the entire PLA2 amino acid sequence and only partly aligned between both 413
predictions, and with the 11 experimental epitopes revealed by the pepscan. For APY a 414
similar result was observed: the servers predicted two different sets of 16 epitopes 415
each, which only partly overlapped between sets, and with the 9 experimental 416
epitopes revealed by the pepscan. By contrast, both servers predicted almost identical 417
epitopes for MOU, which aligned quite faithfully to the experimental epitopes revealed 418
by the antibodies. 419
420
3.6. Vaccination trial 2. Humoral immune response and protective effects induced by 421
joint administration of the recombinant antigens. 422
At 14 days after the third antigen dose (d.p.i.), the immune sera from all 423
vaccinated rabbits showed IgG antibody titres higher than 1/12,800 to each single 424
recombinant. The ODs of all these sera at 1/100 dilution were always close to 1.3 and 425
no significant differences in reactivity to the different recombinant proteins were 426
observed within or between the rabbit groups (Fig. 5). The same was the case of the 427
immune sera obtained at 28 d.p.i. (14 days after the first infestation), although these 428
sera showed ODs slightly higher than their 14 d.p.i. counterparts. 429
When analysed against saliva, the immune sera from vaccinated rabbits at 14 430
d.p.i. showed medium reactivity. The most reactive sera were those from rabbits 431
vaccinated with the antigens formulated in Montanide + CpG (average OD, 0.63), 432
followed by the sera from rabbits vaccinated with the antigens formulated in 433
Montanide alone (average OD, 0.46), and finally by the sera from rabbits vaccinated 434
with the antigens formulated in Freun’s adjuvant (average OD, 0.37). The sera 435
obtained at 28 d.p.i. (14 days after the first infestation) showed notable increases in 436
their ODs to saliva (28 %, 57% and 84 % for groups 1, 2 and 3, respectively); however, 437
these were not statistically significant because of the variability within each group. As 438
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expected, the sera obtained from control rabbits at 14 d.p.i. did not react to saliva but 439
the sera obtained at 28 d.p.i. showed medium-low reactivity (average OD 0.2). 440
The main protective effects observed in this second trial were similar to those 441
of trial 1 and mainly consisted of decreases in feeding, reproduction and survival of the 442
ticks fed on vaccinated animals as compared to the ticks fed on controls. However, in 443
trial 2 these parameters showed higher variation between developmental stages, 444
antigen formulations and infestations (Table 5). 445
In both infestations, the reduction in ingested blood was more significant in 446
females and nymphs than in males. The antigen formulation in Montanide alone and 447
Freun’s,reuce,feeing,in,females,an,nymphs,more,significantly,than,formulation 448
in Montanide plus CpG. The reduction in survival affected males in the first infestation, 449
and males, females and nymphs in the second infestation to a significant extent. In 450
males, the highest mortality was associated with antigen formulated in Montanide plus 451
CpG, while in females and nymphs it was associated with antigen formulated in 452
Freun’s. Female oviposition and fertility rates paralleled each other, showing similar 453
figures for each antigen formulation and infestation. In both infestations, both 454
parameters decreased significantly with the three antigen formulations. In the first 455
infestation, Freun’s, cause, the, greatest reduction (close to 50 %), followed by 456
Montanide alone (around 35 %) and Montanide plus CpG (< 20 %). In the second 457
infestation, the inhibition of female reproduction was increased by Montanide plus 458
CpG and Montanide alone (reaching 36 % and 50 %, respectively) while it decreased 459
slightly with Freun’s,(from 50 % to 40 %) (Table 5). 460
Vaccine efficacy (E) was calculated from the decreases in female survival and 461
fertility for each antigen formulation and infestation (Fig. 6). In both infestations, the 462
antigen formulation in,Freun’s,provie,the,highest,efficacy (50% and 58% in the 1st 463
and 2nd infestation, respectively) followed by Montanide alone (39% and 57%) and 464
Montanide plus CpG (24% and 36%). Interestingly, vaccine efficacy increased in the 465
second infestation for all antigen formulations. Increases were as high as 50 % for 466
Montanide; 46 % for Montanide plus CpG and, 16,%,for,Freun’s,However none of 467
these increases was statistically significant owing variations among the rabbits within 468
each group. 469
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Finally, joint administration of PL;2, ;PY, an, MOU, in, Freun’s, provided a 470
higher vaccine efficacy (50 % in the first infestation) than each of these proteins when 471
they were administered individually in the same adjuvant in trial 1. Thus, a 13.6 % 472
increase in efficacy was obtained in trial 2 as compared to the highest individual 473
efficacy reached in trial 1 (44.2 % for PLA2). 474
475
4. Discussion. 476
An effective vaccine against O. moubata would be of enormous help in the 477
elimination of this tick from synanthropic environments, thus improving the 478
prevention and control of ASF and TBRF in endemic areas. Developing this vaccine has 479
been the objective of our team for several years and with this in mind we have focused 480
on identifying protective proteins from O. moubata that could be expressed as 481
recombinant vaccine antigens. 482
Targeting salivary exposed antigens is interesting since subsequent tick 483
infestations of immunized animals will likely trigger anamnestic antibody responses 484
and serve as booster shots, making re-vaccination of the host unnecessary (Radulovic 485
et al., 2014). Conversely, salivary exposed antigens may have been protected from the 486
host immune response along the co-evolution of the tick-host interaction, rendering 487
them sparingly or non-immunogenic, as is the case of most of the components of O. 488
moubata saliva (Díaz-Martín et al., 2013). Despite this, it has been observed that 489
vaccination with O. moubata salivary anti-haemostatic/anti-inflammatory antigens 490
(ie, Om44), formulate, in, Freun’s, ajuvants, favours, antigen, immunogenicity, an,491
provides protective responses, demonstrating that these molecules are suitable 492
targets for anti-tick vaccines (Díaz-Martín et al., 2015). 493
As mentioned in the introduction, the construction of protein arrays from O. 494
moubata salivary glands allowed us to identify several novel salivary anti-haemostatics 495
(PLA2, APY and MOU) as well as some salivary antigens that were recognized by the 496
serum of Om44-vaccinated and protected animals (PLA2, 7DB-like, RP-60S and HSP90); 497
accordingly, all these salivary components are potential targets for vaccines (Manzano-498
Román et al., 2012).  499
The secreted salivary PLA2 from O. moubata acts as an antagonist ligand for host 500
P-selectin most likely preventing the host haemostatic and inflammatory response 501
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triggered at the tick bite lesion (García-Varas et al., 2010; Manzano-Román et al., 502
2012). P-selectin expressed on activated endothelial cells and platelets interacts with 503
its receptor on leucocytes, the PSLG-1 molecule. This interaction leads to increased 504
thrombin generation at the site of injury and simultaneously stabilizes the platelet plug 505
(Polgar et al., 2005; Cleator et al., 2006; Zarbock et al., 2007). Since this response could 506
prevent tick feeding, blocking the P-selectin/PSGL-1 interaction by PLA2 at the tick bite 507
site seems to be critical for O. moubata to complete its feeding. APY is an orthologue 508
of the O. savignyi apyrase, which acts as a platelet aggregation inhibitor by hydrolysing 509
ADP (Stutzer et al., 2009). MOU is an orthologue of the O. savignyi savignyigrin, which 510
is an antagonist ligand for the aIIbβ3 integrin (or disintegrin) and inhibits platelet 511
aggregation by a number of agonists including ADP. It blocks binding of integrin aIIbβ3 512
on the activated platelets to fibrinogen (Mans et al., 2002). Therefore, blocking the 513
function of PLA2, APY and MOU by vaccine-induced antibodies could impact the tick 514
blood feeding process. 515
Regarding 7DB-like, RP-60S and HSP90, their functions in O. moubata saliva are 516
unknown, although some recent work has reported anti-haemostatic, anti-517
inflammatory and immune-modulatory functions for these kinds of proteins in other 518
organisms, lending further support to their potential value as vaccine targets. Salivary 519
secreted cysteine-rich proteins with 7 disulphide bonds similar to the argasid 7DB 520
protein family (Francischetti et al., 2008a, 2008b; Mans et al., 2008) have been found 521
in ixodid tick saliva, where they seem to be involved in mediating tick anti-haemostatic 522
and anti-complement functions, and RNAi gene-silencing experiments suggest that 523
these proteins could represent interesting vaccine targets (Mulenga et al., 2013; Tirloni 524
et al., 2014). Thus, it is possible that argasid 7DB and 7DB-like proteins could also play 525
similar anti-defensive functions, also representing potential vaccine targets. RP-60S 526
and HSP90 are intracellular housekeeping proteins, but accumulating evidence 527
indicates that in spite of the lack of secretion signals these proteins are actually 528
secreted to tick saliva (Díaz-Martín et al., 2013; Radulovic et al., 2014; Tirloni et al., 529
2014). In addition, recent studies have described extracellular functions for secreted 530
ribosomal proteins and heat shock proteins as anti-inflammatory agents in mammals 531
and parasites (Pockley, 2003; Lv et al., 2013; Poddar et al., 2013; Vélez et al., 2013;). 532
Accordingly, it is conceivable that the secretion of this kind of protein to tick saliva 533
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could be part of the system used by ticks to evade the host inflammatory response to 534
tick feeding, making them candidate antigens to interfere with vaccine-induced 535
antibodies (Radulovic et al., 2014). 536
To evaluate the usefulness of the above-mentioned salivary proteins as vaccine 537
targets, our first objective was to demonstrate their immunogenicity when inoculated 538
as recombinant antigens in rabbits. To do so, the successfully obtained recombinant 539
proteins (all except HSP90, which was toxic for E. coli) were administered individually 540
to the animals in,Freun’s,ajuvants All of them except RP-60S demonstrated strong 541
immunogenicity since they induced the synthesis of high titres of specific antibodies to 542
the homologous recombinant (Fig. 2A), mainly directed to immunodominant epitopes 543
located on the surface of the molecules (Fig. 4B). 544
The sera to PLA2 and APY reacted against their homologous native proteins in 545
saliva, confirming previous evidence of their secretion to this fluid. Regarding PLA2, the 546
specific antibodies revealed three bands of 38, 68 and 100 kDa on the recombinant 547
protein and only recognized the 68 kDa band on the saliva. These results suggest the 548
presence of monomeric and oligomeric forms of this protein, this protein being 549
secreted as a homo-dimer in native saliva. 550
The only band revealed on saliva by the anti-MOU-GST antibodies was 551
compatible in size with that of GST, indicating the presence of GST in O. moubata552
saliva, while the small size of mougrin probably prevented its detection under the 553
electrophoretic conditions used (Tris-Glycine), making it necessary to apply specific 554
conditions to achieve its optimal resolution (Goetz et al., 2004; Schägger, 2006). This is 555
the first report of GST in argasid tick saliva, although GST (and other anti-oxidant 556
proteins) has been already found in the saliva of ixodid ticks, where it is assumed to 557
protect the tick, tick-borne pathogens, and even host tissues from the oxidative stress 558
response to tick-feeding injury (Radulovic et al., 2014). Tick GST has been studied as a 559
target anti-tick vaccine candidate and seems to confer protection in Rhipicephalus 560
microplus and Haemaphysalis longicornis (Parizi et al., 2011). Here, the recognition of 561
O. moubata salivary GST by the anti-MOU-SjGST antibodies does not seem to 562
contribute to the protective effects induced by the MOU-SjGST fusion protein since 563
control rabbits vaccinated with SjGST also recognized the O. moubata salivary GST (not 564
shown) and did not display any protection (Table 4). 565
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The sera to 7DB-like and RB-60S proteins showed very low reactivity against the 566
O. moubata saliva in ELISA and they did not recognize their homologous native protein 567
in Western blots (Fig. 2B). At first sight, these results seem to suggest a lack of 568
secretion of these two proteins to saliva. However, the significant reduction in the 569
blood ingested by the specimens fed on the animals vaccinated with these proteins 570
does not support this idea (Table 4); instead the low immunogenicity of RP-60S and/or 571
post-translational modifications and differences in epitope accessibility between the 572
native and the recombinant versions of these proteins could account for this apparent 573
lack of reactivity (Baker et al., 2010). 574
Regarding the protection achieved, the five recombinants induced qualitatively 575
similar protective responses, which mainly consisted of significant reductions in tick 576
feeding performance, strongly suggesting that all of them would be acting as anti-577
haemostatics to facilitate tick feeding. The reduction in ingested blood and consequent 578
reduction in nutrient availability was later reflected in significant reductions in female 579
oviposition and fertility, especially for PLA2, APY and MOU. In addition, PLA2 induced 580
significant reductions in the survival rate of all the tick developmental stages, 581
suggesting the involvement of this protein in vital processes for ticks, including the 582
production of lipid mediators, the regulation of membrane remodelling, the 583
degradation of foreign phospholipids, and the lysis of host blood cells in the gut lumen 584
(Murakami et al., 2015). Therefore, it could be speculated that this PLA2 and/or other 585
PLA2 isoforms containing cross-reactive epitopes would also be expressed in the tick 586
gut and even in tick reproductive organs. Evidently, this needs further confirmation. 587
In sum, PLA2, APY and MOU showed the highest vaccine efficacies and were 588
considered the best candidates for vaccines, and were therefore subjected to epitope 589
mapping and re-evaluation as a multicomponent vaccine.  590
In most cases, the recognition of a particular epitope by specific antibodies on 591
the antigenic protein is a key event for the immune response to be able to provide 592
protection (Wang et al., 2011; Sharon et al., 2014; Manzano-Román et al., 2015). In 593
agreement with Sharon et al. (2014), our current results strongly suggest that, at least 594
for PLA2, APY and MOU, specific antibodies with high affinity were induced, targeting 595
immunodominant, easily accessible protective epitopes, which most probably interact 596
with host receptors to allow feeding (Fig. 4B). Thus, these epitopes could be included 597
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in the current repertory of target candidates for anti-soft tick vaccines and could even 598
serve as a starting point in the search for conserved or similar protective epitopes on 599
functional orthologues in ixodids that would facilitate the development of broader-600
spectrum anti-tick vaccines (Diaz-Martín et al., 2015). 601
Taken together, the present results confirm that, when administered 602
individually, soft tick salivary antigens are able to induce partial protective immune 603
responses. Such protection mainly consists of impaired tick feeding, most likely as a 604
consequence of the antibody-mediated loss of function of the target antigen at the 605
tick-host interface. Although the exploration of additional adjuvants and immunization 606
protocols could increase the protective efficacy of these antigens, a major factor 607
limiting the vaccine efficacy of individual salivary antigens is the functional redundancy 608
of tick saliva composition, which could compensate the loss of function of the targeted 609
antigen (Chmelar et al., 2012; Kazimírová and Štibrániová, 2013, Wikel, 2013). 610
Accordingly, the use of vaccines formulated with several target antigens would likely 611
increase their protective efficacy (Imamura et al., 2008; Willadsen, 2008b).  612
In this sense, the functional relationship between PLA2, APY and MOU (mainly as 613
anti-platelet aggregation agents) suggested that vaccination with a combination of 614
these proteins could result in a potentially synergistic protective effect. We therefore 615
tested this hypothesis in vaccine trial 2 by administering these three antigens jointly, 616
formulated in two water-in-oil adjuvants, Freund´s and Montanide, which promote 617
prolonged and sustained high antibody titres (Leroux-Roels, 2010; Awate et al., 2013). 618
In addition, we included a third rabbit group in which Montanide was used in 619
combination with the immunostimulant CpG ODN-1826, which is a TLR9 agonist that 620
potentiates humoral responses (Klinman, 2004; Liu et al., 2012, Scheiermann and 621
Klinman, 2014). 622
The results of trial 2 revealed three general trends. First, the administration of 623
the multicomponent vaccine, in, Freun’s, increased vaccine efficacy by 13.6% as 624
compared to the best efficacy of the individual antigens, indicating some additive 625
protective effects rather than a real synergistic effect. Immunological interactions and 626
suppression mechanisms by immunodominant antigens causing 627
suppression/modification of the immune response to co-administered antigens have 628
been described (Insel, 1995). These might have limited more potent additive effects in 629
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the current vaccine trial with these three anti-haemostatics. However, the high 630
antibody titres to each recombinant antigen used (Fig. 5) does not seem to support 631
this idea; instead they suggest the persistence of additional tick salivary anti-632
haemostatics untargeted by the vaccine.  633
Second, the administration of ODN-1826 seemed to favour the synthesis of 634
antibodies recognizing the native antigens in saliva (Fig. 5), but it did not enhance 635
vaccine efficacy (Fig. 6). This increased humoral response could be important for later 636
antigen challenges (Scheiermann and Klinman, 2014), but here this effect was not 637
observed as regards vaccine efficacy, which remained below the vaccine efficacy 638
attained with Montanide alone -and Freund’s- in both infestations (Fig. 6). 639
Third, the higher levels of specific antibodies and vaccine efficacies achieved 640
after tick infestation challenges clearly indicated that the native antigens inoculated 641
with tick saliva during natural contact acted as boosting antigen doses. This notable 642
effect is interesting since it confirms previous observations that “silent”, salivary 643
exposed antigens from ticks can be rendered immunogenic by vaccination (Kotsyfakis 644
et al., 2008) and that the vaccine-induced protective immune response is enhanced by 645
subsequent tick infestations. The increase in vaccine efficacy observed in the second 646
infestation was not attributed to a vaccine-independent acquired immunity upon tick 647
infestation since natural contacts with O. moubata does not induce protective 648
responses in the hosts. This had been observed for rabbits and swine in previous works 649
(Astigarraga et al., 1995; García-Varas et al., 2010) and can be also observed for control 650
rabbits in the current vaccine trial. In these rabbits, the immune response induced by 651
ticks upon the first infestation (Fig. 5) did not resulted in any protection in the second 652
infestation (Table 5). 653
Finally, the high average increase in vaccine efficacy observed in the group 654
vaccinated with Montanide alone suggests that this would be the most convenient 655
adjuvant for the formulation of these antigens. 656
In sum, it appears that a combination of recombinant multi-epitope antigens 657
targeting redundant tick anti-defensive mechanisms could have an important impact 658
on vaccine efficacy. The protection appears to be initiated by the vaccine antigens and 659
is maintained and even amplified by native proteins during subsequent infestations, 660
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although for the time being achieving synergistic protective effects does not seem very 661
feasible. 662
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Figure captions. 850
851
Figure 1. Expression and purification of recombinant phospholipase A2 (A), 7DB family 852
member (B), riboprotein 60S-L10 (C), apyrase (D) and fusion protein MOU-GST (E). 853
Coomassie blue-stained 12% SDS-PAGE gels showing supernatants (S) and pellets (P) 854
from cell lysates before (- IPTG) and after (+ IPTG) the induction of protein expression 855
with IPTG. Panels A to D also include the supernatant and pellet after cell lysate pellet 856
solubilisation with 8M urea. Rightmost lane in each panel shows the purified 857
recombinant protein. MW, molecular weight marker including values in kDa.858
859
Figure 2. Antibody response induced by each recombinant protein in the vaccinated 860
rabbits. (A) Reactivity in ELISA of the anti-recombinant antibodies to both the 861
homologous recombinant and the O. moubata saliva. Values are the mean OD ± SD at 862
492 nm (OD 492 nm immune,sera,−,OD,492 nm pre-immune sera) from each rabbit group. 863
(B) and (C) Western blot: antigenic bands recognized by the anti-recombinant 864
antibodies on the corresponding recombinant protein and O. moubata saliva. Numbers 865
on the left indicate the molecular weight standards. PLA2, phospholipase A2; 7DB-like, 866
putative 7DB family member; RP-60S, riboprotein 60S L10; APY, apyrase; MOU-GST, 867
mougrin-GST fusion protein. 868
869
Figure 3. Trial 1. Vaccine efficacy of the different recombinant antigens calculated as E 870
= 100 (1 - S × F), where S and F represent the reduction in survival and fertility of 871
females fed on vaccinated rabbits as compared to the controls fed on adjuvant and 872
SjGST-treated rabbits.  PLA2, phospholipase A2; 7DB-like, putative 7DB family member; 873
RP-60S, riboprotein 60S L10; APY, apyrase; MOU, mougrin. 874
875
Figure 4. (A) Amino acid sequences of O. moubata PLA2, APY and MOU showing the 876
alpha helices (yellow) and beta sheets (blue) predicted by the Phyre2, the Disopred2 877
Disorder prediction and the I-tasser servers. The linear B-cell epitopes recognized on 878
each protein by the homologous anti-recombinant antibodies are underlined: thin lines 879
represent faint antibody binding and thick lines strong antibody binding (see Suppl. 880
Table 1 for quantification values). In PLA2 and APY, most epitopes map onto α-helices, 881
30 
30 
while in MOU both epitopes map onto the disordered/unstructured region of the 882
protein. (B) Three-dimensional models of O. moubata PLA2, APY and MOU respectively 883
showing the 3, 2 and 2 linear B-cell epitopes strongly recognized by the anti-884
recombinant antibodies in homologous combination. The amino acid sequences and 885
positions of its epitopes are indicated below each protein. Each colour represents a 886
different epitope, except for MOU, where magenta represents the amino acids shared 887
by the two overlapping epitopes identified in this protein. In the three 3-D models the 888
epitopes localize on the surface of the proteins, where they would be easily accessible 889
to antibodies. 890
891
Figure 5. Reactivity in ELISA to PLA2, APY, MOU and O. moubata saliva of the immune 892
sera from rabbits vaccinated in trial 2. Sera were obtained at 14 and 28 days after the 893
third antigen dose (d.p.i.). Values are the mean OD ± SD at 492 nm (OD 492 nm immune 894
sera, −, OD, 492 nm pre-immune sera) from each rabbit group. The control group was 895
treated with Montanide ISA 50 V2 and CpG ODN-1826; Ag-Mont-CpG, antigen 896
emulsified in Montanide ISA 50 V2 with CpG ODN-1826; Ag-Mont, antigen emulsified 897
in Montanide alone; Ag-Freund, antigen emulsified in Freun’s alone. 898
899
Figure 6. Trial 2. Vaccine efficacy of the different formulations in both infestations was 900
calculated as E = 100 (1 - S × F), where S and F represent the reduction in survival and 901
fertility of females fed on vaccinated rabbits as compared to those fed on control 902
rabbits treated with Montanide plus CpG. Ag-Mont-CpG, antigen emulsified in 903
Montanide ISA 50 V2 with CpG ODN-1826; Ag-Mont, antigen emulsified in Montanide 904
alone; Ag-Freun,antigen,emulsifie,in,Freun’s,alone905
Table 1. Recombinant plasmids (templates) and primers used for amplification of the cDNAs 
coding for the target proteins. Primers include suitable restriction sites (underlined) to assist in 
the subcloning into the corresponding expression vector (last column) as well as additional 
nucleotides in 5’ to increase the activity of the restriction enzymes involved. (t), proteins for 
which a truncated version without signal peptide was amplified; PLA2, phospholipase A2; 7DB-
like, putative 7DB family member; RP-60S, riboprotein 60S L10; HSP90, heat shock protein 90; 
APY, apyrase; MOU, mougrin. 
Target 
protein
Template 
plasmids
Primer name Primer sequence Restriction 
enzyme
Expression 
vector
PLA2
Clones in 
pANT7_GST
PLA2_KpnI55     5’-TTCGGTACCATGACTAAAGAAAACCAGACC
KpnI
pQE-30
PLA2_KpnI33  5’-TTCGGTACC AGTCATTTTGTCGTCTTTATTG
7DB-like (t)
tr7DB_KpnI55 5’-TTCGGTACCACTTTCATCATAGAAGATCTTCC
7DB_KpnI33  5’-TTCGGTACCTCACGGCGACGCATTTGTCAC
RP-60S 
Rib_KpnI55 5’-TTCGGTACCATGGGTCGCCGTCCGGCAAG
Rib_KpnI3 5’-TTCGGTACCTCAGAGGTCCGTGGCCGCTGT
HSP90 pSC-A-HSP90
Hsp90Kpn55 5’-TTCGGTACCATGCCAGAAGAAGCTCAAATG
KpnI
Hsp90Kpn33 5’-TTCGGTACCTTAGTCTACTTCCTCCATGC
APY (t) Clones in 
pDONR_222
trApi55Kpn 5’-TTCGGTACC AAGCCTGCAACGACTCCG
Api33Kpn 5’-TTCGGTACCTTAGACCCAGATCTCTTGCTT
MOU
MougrinEcoRI55 5’-CCGGAATTCATGCAGGCGAAAATCTTGGT
EcoRI pGEX-4T-1 MougrinEcoRI33 5’-CCGGAATTC TTACCATTTTTCTCCGCATAG
Table 1
Table 2. PCR conditions for amplification of cDNAs coding for the target proteins. (t), proteins 
for which a truncated version without signal peptide was amplified; PLA2, phospholipase A2; 
7DB-like, putative 7DB family member; RP-60S, riboprotein 60S L10; HSP90, heat shock protein 
90; APY, apyrase; MOU, mougrin. 
Target protein PCR conditions
PLA2 2 min 94 °C 5 cycles (94 °C 15 s, 56 °C 30 s, 72 °C 40 s) + 30 cycles (94 °C 15 s, 62 °C 30 s, 72 °C 40 s) 7 min 72 °C
7DB-like (t) 2 min 94 °C 5 cycles (94 °C 15 s, 60 °C 30 s, 72 °C 40 s) + 30 cycles (94 °C 15 s, 66 °C 30 s, 72 °C 40 s) 7 min 72 °C
RP-60S 2 min 94 °C 5 cycles (94 °C 15 s, 66 °C 30 s, 72 °C 40 s) + 35 cycles (94 °C 15 s, 72 °C 30 s, 72 °C 90 s) 7 min 72 °C
HSP90 2 min 94 °C 5 cycles (94 °C 15 s, 56 °C 30 s, 72 °C 40 s) + 30 cycles (94 °C 15 s, 60 °C 30 s, 72 °C 40 s) 7 min 72 °C
APY (t) 2 min 94 °C 5 cycles (94 °C 15 s, 56 °C 30 s, 72 °C 40 s) + 30 cycles (94 °C 15 s, 62 °C 30 s, 72 °C 40 s) 7 min 72 °C
MOU 2 min 94 °C 5 cycles (94 °C 15 s, 56 °C 30 s, 72 °C 40 s) + 30 cycles (94 °C 15 s, 62 °C 30 s, 72 °C 40 s) 7 min 72 °C
Table 2
Table 3. Nucleotide sequences coding for the target proteins: GenBank accession number and 
size in base pairs (bp). Protein sequences: size in number of amino acid (aa), theoretical 
isoelectric point (pI) and molecular weight (MW) and predicted presence/absence of signal 
peptide, transmembrane helices (TH), non-classical secretion signals and GPI anchors. PLA2, 
phospholipase A2; 7DB-like, putative 7DB family member; RP-60S, riboprotein 60S L10; HSP90, 
heat shock protein 90; APY, apyrase; MOU, mougrin. 
Nucleotide sequence Amino acid sequence
Protein 
name
GenBank 
accession no.
Size 
(bp)
Size 
(aa)
pI MW
(kDa)
Signal 
peptide
(aa)
TH Non-classical
secretion
signal 
GPI 
anchor
PLA2 KC908103.1 816 271 5.71 31.44 no no yes no
7DB-like KC908104.1 342 113 4.22 12.38 Yes (1-17) no yes no
RP-60S KC908109.1 624 207 10.66 23.56 no no no no
HSP90 KC908107.1 1692 563 5.03 65.73 no no no no
APY KC908110.1 1755 584 8.69 65.23 Yes (1-18) no yes no
MOU KC908105.1 192 63 4.64 7.21 Yes (1-21) yes no no
Table 3
Table 4. Effect of the individual vaccination with each recombinant antigen on O. moubata specimens fed on control and vaccinated 
rabbits. Results are shown as mean ± standard deviation for each rabbit group. Means were compared between ticks fed on 
vaccinated and control rabbits (merged adjuvant-treated and SjGST-vaccinated rabbits) by one-way ANOVA followed by the Dunnett’s 
t-test. Values inside parentheses represent the percentage of reduction in the corresponding parameter (or percentage increase for 
mortality rates) respect to the merged controls. * p < 0.05; ** p < 0.01. SjGST, Schistosoma japonicum glutathione-S transferase; PLA2, 
phospholipase A2; 7DB-like, putative 7DB family member; RP-60S, riboprotein 60S L10; APY, apyrase; MOU-GST, mougrin-GST fusion 
protein.  
Parameter Developmental 
stage
Merged control 
(adjuvant and
SjGST,  n = 6)
Control rabbits 
(adjuvant)
Control rabbits 
(SjGST)
PLA2 
vaccinated 
rabbits
(% reduction)
7DB-like
vaccinated 
rabbits
(% reduction)
RP-60S 
vaccinated 
rabbits
(% reduction)
APY vaccinated 
rabbits
(% reduction)
MOU-GST 
vaccinated 
rabbits
(% reduction)
Ingested blood (mg) Males 28.1 ± 4.3 27.8 ± 4.3 28.4 ± 5.1 27.2 ± 3.2
(3.2)
27.2 ± 6.5
(3.1)
25.3 ± 0.3
(10.2)
19.6 ± 1.3
(30.5)**
19.7 ± 2.7
(30.0)**
Females 233.1 ± 16.5 239.8 ± 17.6 219.7 ± 6.3 186.4 ± 19.2
(20.1)**
173.3 ± 26.4
(25.6)**
204.4 ± 14.5
(12.3)**
172.2 ± 5.7
(26.1)**
185.4 ± 18.2
(20.5)**
Nymphs-2 26.3 ± 3.1 26.4 ± 3.1 26.3 ± 4 21.6 ± 2.5
(18.1)**
21.5 ± 0.9
(18.6)**
21.4 ± 1.6
(18.8)**
15.9 ± 2.1
(39.7)**
19.9 ± 4.3
(24.2)**
Mortality (%) Males 4.3  ± 3.6 6 ± 2 2.6  ± 4.1 18.6 ± 3.9
(14.3)**
8 ± 0
(3.7)
10.7 ± 3.9
(6.4)
16 ± 4.4
(11.7)**
5.3 ± 3.9
(1)
Females 5 ± 3 5.6 ± 2.7 4.4 ± 3.4 31.6 ± 21.1 
(26.6)**
4.4 ± 3.3
(0)
15.6 ± 11.7
(10.6)*
2.2 ± 3.2
(0)
8.9 ± 3.2
(3.9)
Nymphs-2 2.7 ± 3.4 5.3 ± 3 0 ± 0 11.3 ± 7.9
(8.4)**
6 ± 2.9
(3.3)
12 ± 1.7
(9.3)**
4 ± 0
(1.3)
2.7 ± 3.9
(0)
Oviposition 
(no. eggs/female)
Females 209.3  ± 14.9 205.3  ± 19.8 213.3 ± 7.9 160.5 ± 36.8
(23.3)**
192.9 ± 5.9
(8.7)
181.7 ± 2
(13.2)*
153.6 ± 6.1
(26.6)**
142.5 ± 8.9
(31.9)**
Fertility 
(no. nymphs/female)
Females 189.1 ± 14.3 191.3 ± 20 186.8 ± 4.7 146.3 ± 32
(22.6)**
168.9 ± 10.1
(10.7)*
171.9 ± 5
(9.1)
140.3 ± 8,6
(25.8)**
116.9 ± 25.2
(38.2)**
Table 4
Table 5. Effect of the vaccination with the three recombinant antigens administered together in different formulations on O. moubata specimens fed on 
control and vaccinated rabbits in two infestations performed 14 days apart. For each infestation, results are shown as mean ± standard deviation for each 
rabbit group. Means were compared between ticks fed on vaccinated and control rabbits by one-way ANOVA followed by the Dunnett’s t-test. Values inside 
parentheses represent the percentage of reduction in the corresponding parameter (or percentage increase for mortality rates) respect to the control. * p < 
0.05; ** p < 0.01. Control group was treated with Montanide ISA 50 V2 and CpG ODN-1826, without antigen. Group 1 was immunized with the 
three recombinants (PLA2, APY and MOU) emulsified in Montanide ISA 50 V2 with CpG ODN-1826; group 2 was immunized with the three 
recombinants emulsified in Montanide ISA 50 V2, and group 3 was immunized with the three recombinants emulsified in Freund’s.
First infestation Second infestation
Parameter Developmental 
stage
Control Group 1
Ag-Mont-CpG
(% reduction)
Group 2
Ag-Montanide
(% reduction)
Group 3
Ag-Freund’s
(% reduction)
Control Group 1
Ag-Mont-CpG
(% reduction)
Group 2
Ag-Montanide
(% reduction)
Group 3
Ag-Freund’s
(% reduction)
Ingested blood 
(mg) 
Males 23.1 ± 1.8 22.1 ± 5.1
(4.7)
21.1  ± 5.4
(8.8)
22.1 ± 1.8
(4.7)
23.3 ± 2.7 18.8 ± 3.7
(19.3)
22.7 ± 0.8
(2.8)
17.2 ± 11.7
(26.1)
Females 196.4 ± 14.5 193.3 ± 24.8
(1.6)
150.8 ± 17.9
(23.2)**
154.4 ± 12
(21.4)**
243.9 ± 12.8 237.5 ± 33.2
(2.6)
171.2 ± 5.9
(29.8)**
197.4 ± 23.6
(19)*
Nymphs-3 47.2 ± 2.3 34.7 ± 27.5
(26.4)*
31.9 ± 1.7
(32.5)**
36.3 ± 6.1
(23.2)*
47.3 ± 1.7 46.9 ± 1.4
(1)
41.8 ± 1.8
(11.7)
39.1 ± 5.2
(17.3)**
Mortality (%) Males 5.3  ± 2.3 18.7 ± 7.4
(13.4)**
16 ± 4.4
(10.7)**
5.3 ± 1.9
(0)
4 ± 4 16.1 ± 3.8
(12.1)**
6 ± 2.2
(2)
10.7 ± 2.0
(6.7)**
Females 7.1 ± 0.8 15.5 ± 3.4
(8.4)
13.3 ± 0.0
(6.2)
8.9 ± 8.7
(1.8)
4.4 ± 3.8 20 ± 10.3
(15.6)
16.7 ± 3.7
(12.3)
31.1 ± 13.1
(26.7)**
Nymphs-3 2.7 ± 1.1 1.3 ± 2.1
(0)
1.1 ± 1.1
(0)
4.7 ± 3.6
(2)
10.7 ± 8.1 10 ± 4.7
(0)
13 ± 5.4
(2.3)
24.7 ± 9
(14)**
Oviposition (no. 
eggs/female)
Females 222.3  ± 18.6 184.6 ± 18.2
(17.0)**
144.9 ± 2.3
(34.8)**
116.7 ± 4
(47.5)**
221.2  ± 25.4 155.9 ± 27.3
(26.2)*
113.6 ± 28.7
(46.2)**
126.3 ± 33.7
(40.2)*
Fertility  (no. 
nymphs/female)
Females 190.8 ± 9.9 159.9 ± 8.1
(16.2)**
125.5 ± 9.2
(34.2)**
100.7 ± 3.8
(47.2)**
187.3 ± 19.2 140.1 ± 21.9
(25.2)*
91.1 ± 39.5
(51.4)**
110.5 ± 28.8
(41)**
Table 5
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